Cefquinome은 제4세대 cephalosporin으로 동물전용의약품으로 개발되었으며, ${\beta}$-lactamases에 대해서 매우 안정하고, 그람 음성 세균 및 양성 세균에 대한 광범위한 살균력을 가지고 있다. 본 연구는 현재 시판중인 cefquinome 주사제를 이유 자돈에 2 mg/kg 용량으로 근육 주사한 후 약물동태학적 특성을 파악하여 두 제제의 생물학적 동등성을 평가하였다. Cefquinome의 혈중 농도는 액체크로마토그래프/질량분석기를 이용하여 분석하였으며, 생물학적 동등성을 판정하기 위한 약물동태학적 인자로는 혈중 최고 농도 ($C_{max}$)와 혈장 농도 곡선하 면적 ($AUC_{0{\rightarrow}{\infty}}$)을 사용하였다. 시험약과 대조약의 혈중 최고 농도는 $4.34{\pm}0.58{\mu}g/mL$과 $4.22{\pm}0.47{\mu}g/mL$로 각각 나타났으며, 혈장 농도 곡선 하 면적은 $10.43{\pm}1.96{\mu}g{\cdot}h/mL$과 $10.25{\pm}2.98{\mu}g{\cdot}h/mL$로 관찰되었다. 로그변환한 약물동태학적 인자의 평균비율의 90% 신뢰 구간은 $C_{max}$의 경우 0.941-1.115이었고, $AUC_{0{\rightarrow}{\infty}}$의 경우 0.927-1.172로서 생물학적 동등성 기준인 0.8-1.25를 모두 만족시켰다. 이상의 결과로 시판중인 두 cefquinome 제제는 생물학적으로 동등하다고 판단된다.
Cefquinome은 제4세대 cephalosporin으로 동물전용의약품으로 개발되었으며, ${\beta}$-lactamases에 대해서 매우 안정하고, 그람 음성 세균 및 양성 세균에 대한 광범위한 살균력을 가지고 있다. 본 연구는 현재 시판중인 cefquinome 주사제를 이유 자돈에 2 mg/kg 용량으로 근육 주사한 후 약물동태학적 특성을 파악하여 두 제제의 생물학적 동등성을 평가하였다. Cefquinome의 혈중 농도는 액체크로마토그래프/질량분석기를 이용하여 분석하였으며, 생물학적 동등성을 판정하기 위한 약물동태학적 인자로는 혈중 최고 농도 ($C_{max}$)와 혈장 농도 곡선하 면적 ($AUC_{0{\rightarrow}{\infty}}$)을 사용하였다. 시험약과 대조약의 혈중 최고 농도는 $4.34{\pm}0.58{\mu}g/mL$과 $4.22{\pm}0.47{\mu}g/mL$로 각각 나타났으며, 혈장 농도 곡선 하 면적은 $10.43{\pm}1.96{\mu}g{\cdot}h/mL$과 $10.25{\pm}2.98{\mu}g{\cdot}h/mL$로 관찰되었다. 로그변환한 약물동태학적 인자의 평균비율의 90% 신뢰 구간은 $C_{max}$의 경우 0.941-1.115이었고, $AUC_{0{\rightarrow}{\infty}}$의 경우 0.927-1.172로서 생물학적 동등성 기준인 0.8-1.25를 모두 만족시켰다. 이상의 결과로 시판중인 두 cefquinome 제제는 생물학적으로 동등하다고 판단된다.
Cefquinome, a fourth generation cephalosporin, has been solely used for veterinary medicine and has a broad antibacterial spectrum against gram-negatives and gram-positives being very stable to ${\beta}$-lactamases. This study was conducted to evaluate the bioequivalence of two cefquinome...
Cefquinome, a fourth generation cephalosporin, has been solely used for veterinary medicine and has a broad antibacterial spectrum against gram-negatives and gram-positives being very stable to ${\beta}$-lactamases. This study was conducted to evaluate the bioequivalence of two cefquinome 2.5% products in piglets. Plasma cefquinome concentrations were analyzed by liquid chromatography-mass spectrometry (LC/MS). Mean maximum concentration ($C_{max}$) of test product ($Cequus^{(R)}$) and reference product ($Cobactan^{(R)}$) were $4.34{\pm}0.58$ and $4.22{\pm}0.47{\mu}g/mL$, and mean area under the concentration time curve ($AUC_{0{\rightarrow}{\infty}}$) values were $10.43{\pm}1.96$ and $10.25{\pm}2.98{\mu}g{\cdot}h/mL$, respectively. The 90% confidence intervals for the ratio of $C_{max}$ (0.941-1.115), and $AUC_{0{\rightarrow}{\infty}}$ (0.927-1.172) values for the test and reference products were within the acceptable bioequivalence limit of 0.80-1.25. It is concluded that two commercial cefquinome injectable solutions are bioequivalent in their extent of drug absorption in piglets.
Cefquinome, a fourth generation cephalosporin, has been solely used for veterinary medicine and has a broad antibacterial spectrum against gram-negatives and gram-positives being very stable to ${\beta}$-lactamases. This study was conducted to evaluate the bioequivalence of two cefquinome 2.5% products in piglets. Plasma cefquinome concentrations were analyzed by liquid chromatography-mass spectrometry (LC/MS). Mean maximum concentration ($C_{max}$) of test product ($Cequus^{(R)}$) and reference product ($Cobactan^{(R)}$) were $4.34{\pm}0.58$ and $4.22{\pm}0.47{\mu}g/mL$, and mean area under the concentration time curve ($AUC_{0{\rightarrow}{\infty}}$) values were $10.43{\pm}1.96$ and $10.25{\pm}2.98{\mu}g{\cdot}h/mL$, respectively. The 90% confidence intervals for the ratio of $C_{max}$ (0.941-1.115), and $AUC_{0{\rightarrow}{\infty}}$ (0.927-1.172) values for the test and reference products were within the acceptable bioequivalence limit of 0.80-1.25. It is concluded that two commercial cefquinome injectable solutions are bioequivalent in their extent of drug absorption in piglets.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
제안 방법
The accuracy and the precision of the assays for intra-day and inter-day determinations were evaluated by the analysis of QC samples at the concentrations of 0.02, 1.0 and 5.0 µg/mL (n = 4 for each concentration) on the same day and on 4 different days, respectively.
The study was conducted with a randomized, open-label, single dose, two-period crossover design. The animals were divided into two groups of 6 animals each.
대상 데이터
The study was conducted with a randomized, open-label, single dose, two-period crossover design. The animals were divided into two groups of 6 animals each. One group was i.
This study was performed in 12 healthy cross-bred (Landrace × Duroc × Yorkshire) piglets weighing 23-26 kg and aged about 7 weeks.
데이터처리
There was no statistically significant difference between the test and reference drugs in the logarithmically transformed AUC0-∞ as well as logarithmically transformed Cmax values, using analysis of variance (ANOVA).
성능/효과
The 90% confidence interval for the ratio of the logarithmically transformed AUC0-∞ values of Cequus® over those of Cobactan® lay between 0.93 and 1.17, while Cmax values lay between 0.94 and 1.12.
The two commercial cefquinome preparations were considered bioequivalent if the 90% confidence intervals (CI) for test/reference ratios of logarithmically transformed Cmax, and AUC0 → ∞ were within the range of 0.80-1.25 (p < 0.05).
참고문헌 (16)
Al-Taher AA. Pharmacokinetics of cefquinome in camels. J Anim Vet Adv 2010; 9: 848-852.
CVMP. Cefquinome (Extension to horses). Summary reprot (3) EMEA/MRL/888/03-FINAL. London: European Agency for the Evaluation of Medicinal Products, 2003.
CVMP. Cefquinome summary report EMEA/MRL/005/95. London: European Agency for the Evaluation of Medicinal Products, 1995.
Ehinger AM, Schmidt H, Kietzmann M. Tissue distribution of cefquinome after intramammary and "systemic" administration in the isolated perfused bovine udder. Vet J 2006; 172: 147-153.
El-Gendy AAM, Tohamy MA, Radi AM. Pharmacokinetic profile and some pharmaco- dynamic aspects of cefquinome in chickens. Beni-Suef Vet Med J 2009; 19: 33-37.
Grahnen A. Design of bioavailability studies. Pharm Int 1984; 5: 100-103.
Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Therapeut 1990; 28: 72-78.
Korea Animal, Plant and Fisheries Quarantine and Inspection Agency. In: The guideline of bioequivalence test for veterinary drugs. Korea: 2011; No. 2011-12.
Korea Animal, Plant and Fisheries Quarantine and Inspection Agency. In: The guideline of residue test for veterinary drugs. Korea: 2011; No. 2011-16.
Li XB, Wu WX, Su D, Wang ZJ, Jiang HY, Shen JZ. Pharmacokinetics and bioavailability of cefquinome in healthy piglets. J Vet Pharmacol Ther 2008; 31: 523-527.
Limbert M, Isert D, Klesel N, Markus A, Seeger K, Seibert G, Schrinner E. Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 1991; 35: 14-19.
Lui B, Zhang C, Zhang X, Yang S, Yu J, Sun J, Lui Y. Pharmacokinetics and bioavailability of cefquinome in crossbred wild boars. J Vet Pharmacol Therap 2012; doi:10.1111/j.1365-2885.2011.01360.x.
Rose M, Thomas V, Nordmann P. In vitro activity of third and fourth generation cephalosporins against E. coli strains expressing plasmid-encoded AmpC cephalosporinases. In: Risk Management for the Limitation of Antibiotic Resistance, Scientific Symposium. Federal Office of Consumer Protection and Food Safety, Berlin, Germany, 2004; 15-16.
Uney K, Altan F, Elmas M. Development and validation of an HPLC method for the determination of cefquinome in sheep plasma and its application to the pharmacokinetic study. Antimicrob Agents Chemother 2010; 55: 854-859.
Westlake WJ. Bioavailability and bioequivalence of pharmaceutical formulations. In: Biopharmaceutical Statistics for Drug Development, New York: Marcel Dekker. 1988: 329-352.
Yuan L, Sun J, Wang R, Sun L, Zhu L, Luo X, Fang B, Liu Y. Pharmacokinetics and bioavailability of cefquinome in healthy ducks. Am J Vet Res 2011; 72: 122-126.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.